Please use this identifier to cite or link to this item:
Title: Minimal removal of iron-dextran by conventional haemodialysis. An in vivo study
Authors: Bailie, G.R.
Handa, J.J.
Tang, L.
Low, C.L. 
Eisele, G.
Issue Date: 1997
Citation: Bailie, G.R.,Handa, J.J.,Tang, L.,Low, C.L.,Eisele, G. (1997). Minimal removal of iron-dextran by conventional haemodialysis. An in vivo study. Clinical Drug Investigation 14 (1) : 12-15. ScholarBank@NUS Repository.
Abstract: Iron-dextran may be administered during haemodialysis by slow infusion through the venous access port for the management of iron deficiency in patients treated with erythropoietin. This technique is time-efficient and convenient. The degree to which haemodialysis removes iron-dextran in vivo, however, is unknown. The purpose of this study was to measure the removal of iron-dextran in patients undergoing haemodialysis. Eight patients were enrolled into this open label, single dose, mass transfer study. All were stable patients, treated by haemodialysis for at least 1 month and with a stable baseline average haematocrit of 30.9 ± 1.9%. All 8 patients used a Terumo® 175 cuprammonium dialyser and all received 1 g of intravenous iron-dextran infused over 1 hour during dialysis. Dialysate was collected for an average of 160 ± 30 minutes, was concentrated by lyophilisation, and assayed for iron-dextran content by spectrophotometry. The amount of iron-dextran removed by haemodialysis was determined. Six of the 8 patients showed no detectable amounts of iron-dextran in the dialysate, while 2 showed less than 2% of the total dose given. Haemodialysis removed 5 mg of iron during a 110-minute session in 1 patient, and 17 mg of iron during a 188-minute session in a second patient. Both patients were dialysed with the Terumo® 175 dialyser, reprocessed once. Our study concluded that there is minimal removal of iron-dextran by conventional haemodialysis in vivo. Administration of iron dextran during haemodialysis is convenient and efficient, and does not warrant a change in dosage schedule.
Source Title: Clinical Drug Investigation
ISSN: 11732563
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

checked on Aug 3, 2018

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.